sPARK.
2020

Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection

Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, Capanu M, …

Clinical Cancer Research 26(13), 3239–3247

sPARK LabWungki ParkEileen O'Reilly
HRDDDRGenomicsPDAC
253Citations
2020Year

Research Programs

ProgramDNA Damage Repair & PARP-Immunotherapy

Related by topic

Publication · DDR, HRD, PDACPembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR TrialPublication · Genomics, PDACAlterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinomaPublication · Genomics, PDACClinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survivalPublication · PDAC, GenomicsDistinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancerPublication · Genomics, PDACEarly-onset pancreas cancer: clinical descriptors, genomics, and outcomesProject / Trial · DDR, HRDPOLAR Trial

Local graph

Tap a node to select · use + / − to zoom · enable Move graph to drag

Browse nodes (7)
Open full graph →